Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams

References

• Tang S, Both S, Bentefour H, et al. Improvement of prostate treatment by anterior proton fields. Int J Radiat Oncol Biol Phys. 2012;83:408–418.
   PubMed Web of Science ®Google Scholar
• Cuaron J, Harris A, Chon B, et al. Anterior-oriented proton beams for prostate cancer: A multi-institutional experience. Acta Oncol. 2015;54:868–874.
   PubMed Web of Science ®Google Scholar
• Hatiboglu G, Pinkawa M, Vallée J-P, et al. Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int. 2012;110:E647–E652.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Piroth MD, Holy R, et al. Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall. Radiother Oncol. 2013;106:220–224.
   PubMed Web of Science ®Google Scholar
• Weber DC, Zilli T, Vallee JP, et al. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study. Int J of Radiat Oncol Biol Phys. 2012;84:e311–e318.
   PubMed Web of Science ®Google Scholar
• Pieczonka CM, Mariados N, Sylvester, et al. Hydrogel spacer application technique, patient tolerance and impact on prostate intensity modulated radiation therapy: results from a prospective, multicenter, pivotal randomized controlled trial. Urol Pract. 2016;3:141–146.
   Google Scholar
• Hutchinson R, Sundaram V, Folkert M, et al. Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. Urol Oncol Elsevier. 2016;34:e19–e26.
   Google Scholar
• Underwood T, Giantsoudi D, Moteabbed M, et al. Can we advance proton therapy for prostate? considering alternative beam angles and relative biological effectiveness variations when comparing against intensity modulated radiation therapy. Int J of Radiat Oncol Biol Phys. 2016;95:454–464.
   PubMed Web of Science ®Google Scholar
• Perl J, Shin J, Schümann J, et al. TOPAS: an innovative proton Monte Carlo platform for research and clinical applications. Med Phys. 2012;39:6818–6837.
   PubMed Web of Science ®Google Scholar
• Schuemann J, Giantsoudi D, Grassberger C, et al. Assessing the clinical impact of approximations in analytical dose calculations for proton therapy. Int J Radiat Oncol Biol Phys. 2015;92:1157–1164.
   PubMed Web of Science ®Google Scholar
• McNamara AL, Schuemann J, Paganetti H. A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published in vitro cell survival data. Phys Med Biol. 2015;60:8399–8416.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Gay H, Jackson A, et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76:S123–S129.
   PubMed Web of Science ®Google Scholar
• Viswanathan AN, Yorke ED, Marks LB, et al. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010;76:S116–S122.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101.
   PubMed Web of Science ®Google Scholar
• Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021–1031.
   PubMed Web of Science ®Google Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol. 2012;51:963–974.
   PubMed Web of Science ®Google Scholar
• Efstathiou J, Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer. 2016. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT01617161 [cited 2016 Jan 5].
   Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–1060.
   PubMed Web of Science ®Google Scholar
• Katz AJ, Santoro M, Diblasio F, et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8:118.
   PubMed Web of Science ®Google Scholar
• Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J of Radiat Oncol Biol Phys. 2007;69:444–453.
   PubMed Web of Science ®Google Scholar
• Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011;6:3.
   PubMed Web of Science ®Google Scholar
• Heikkilä V-P. PEG spacer gel and adaptive planning vssingle plan in external prostate radiotherapy—clinical dosimetry evaluation. BJR. 2015;88:20150421–20150422.
   PubMed Web of Science ®Google Scholar
• Thörnqvist S, Muren LP, Bentzen L, et al. Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets. Acta Oncol. 2013;52:521–527.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Kawamura H, Sakai M, et al. Changes in rectal dose due to alterations in beam angles for setup uncertainty and range uncertainty in carbon-ion radiotherapy for prostate cancer. PLoS One. 2016;11:e0153894.
   Google Scholar
• Tang S, Deville C, McDonough J, et al. Effect of intrafraction prostate motion on proton pencil beam scanning delivery: a quantitative assessment. Int J Radiat Oncol Biol Phys. 2013;87:375–382.
   PubMed Web of Science ®Google Scholar
• Thor M, Casares-Magaz O, Muren LP, et al. A method for evaluation of proton plan robustness towards inter-fractional motion applied to pelvic lymph node irradiation. Acta Oncol. 2015;54:1643–1650.
   PubMed Web of Science ®Google Scholar
• Hoesl M, Deepak S, Moteabbed M, et al. Clinical commissioning of an in vivo range verification system for prostate cancer treatment with anterior and anterior oblique proton beams. Phys Med Biol. 2016;61:3049–3062.
   PubMed Web of Science ®Google Scholar
• Teh AY, Ko HT, Barr G, et al. Rectal ulcer associated with SpaceOAR hydrogel insertion during prostate brachytherapy. BMJ Case Rep. 2014. doi: 10.1136/bcr-2014-206931.
   Google Scholar
• Habl G, Uhl M, Katayama S, et al. Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized phase II study-The IPI trial. Int J Radiat Oncol Biol Phys. 2016;95:435–443.
   PubMed Web of Science ®Google Scholar
• Qi XS, Wang JP, Gomez CL, et al. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. Radiother Oncol. 2016;121:113–117.
   PubMed Web of Science ®Google Scholar
• Thor M, Olsson C, Oh JH, et al. Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. Acta Oncol. 2015;54:1326–1334.
   PubMed Web of Science ®Google Scholar